文献速递骨软组织肉瘤与黑色素瘤

质子泵抑制剂及其他合并用药对接受BRAF/MEK抑制剂治疗的晚期黑色素瘤患者的临床影响

Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors.
PubMed 文献 · Eur J Cancer · 2023-12-09

该观察性研究纳入2013至2020年波尔多大学医院192例接受BRAF/MEK抑制剂治疗的晚期黑色素瘤患者,记录靶向治疗开始前1个月至开始后3个月内的合并用药。多变量分析显示质子泵抑制剂是唯一与总生存期和无进展生存期显著缩短相关的合并用药,合并用药未影响靶向治疗相关毒性的风险、类型或发生时间。

要点

  • 在192例接受BRAF/MEK抑制剂治疗的晚期黑色素瘤患者中,质子泵抑制剂是唯一在多变量分析中与总生存期和无进展生存期显著缩短相关的合并用药。
  • 合并用药未影响靶向治疗相关毒性的风险、类型或发生时间。
  • 部分患者残余血浆靶向治疗浓度在质子泵抑制剂使用者与非使用者之间无差异。

核心结论

  • 合并用药,尤其是质子泵抑制剂,必须在开始靶向治疗时仔细评估。

研究设计与样本

  • 观察性研究,纳入2013年至2020年波尔多大学医院接受BRAF/MEK抑制剂治疗的晚期黑色素瘤患者,共192例。
  • 记录靶向治疗开始前1个月至开始后3个月内的合并用药,并按作用机制或代谢方式分类。
  • 采用单变量和多变量Cox回归分析生存数据,并使用混合数据因子分析(FAMD)评估多因素联合效应,同时评估合并用药对靶向治疗相关毒性的影响。

主要发现

  • 多种合并用药与显著缩短的总生存期和/或无进展生存期相关,但质子泵抑制剂是唯一在考虑所有合并用药和特定预后因素的多变量分析中具有显著影响的合并用药。
  • 合并用药未影响靶向治疗相关毒性的风险、类型或发生时间。
  • FAMD进一步揭示了各因素对肿瘤学结局的影响。
  • 在部分患者中,残余血浆靶向治疗浓度在质子泵抑制剂使用者与非使用者之间无差异。

临床怎么用

  • 原文结论指出,合并用药尤其是质子泵抑制剂必须在开始靶向治疗时仔细评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF and MEK had significantly improved management of advanced melanoma with BRAFV600 mutation over the last decade, we aimed to investigate the possible influence of co-mediations on the efficacy and toxicity of these targeted therapies (TT). METHODS: We conducted an observational study identifying patients with advanced melanoma treated with BRAF/MEK inhibitors between 2013 and 2020 in the Bordeaux University Hospital. Co-medications given within 1 month before until 3 months after the initiation of targeted therapy were recorded and classified by their mechanism or by their metabolism. Survival data were analyzed with univariable and multivariable cox regression and the combined effect of multiple factors was evaluated using a factor analysis of mixed data (FAMD). The impact of co-medications on toxicity related to TT was also assessed. RESULTS: A total of 192 patients were included. Although several co-medications were associated with significantly shorter overall survival (OS) and/or progression-free survival (PFS), PPIs was the only co-medication with a significant impact in multivariable analysis considering all co-medications and specific prognostic factors. Co-medications did not influence the risk, type, or timing of TT-related toxicity. Additional FAMD revealed the impact of each factor on the oncological outcomes. In a subgroup of patients, residual plasma TT concentration was available and did not differ between PPIs users and non-users. CONCLUSION: Co-medications, especially PPIs, must be carefully assessed at the time of TT initiation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ramel E, Prey S, Dutriaux C, et al. Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors. Eur J Cancer. 2023. PMID: 38113780. doi:10.1016/j.ejca.2023.113477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。